Three-Target Merck Serono Collaboration
F-Star Scores $691M Antibody Deal for Inflammatory Disease
By Nuala Moran
Thursday, September 8, 2011
LONDON Antibody engineering specialist F-Star GmbH landed a second partner for its novel antibody formats, signing up Merck Serono SA in an inflammatory disease deal with a headline value of €492 million (US$691.1 million).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.